trial
as of 2026-07-01Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
NCTId NCT00595504
at a glance
Phase 4 · Completed
Enrollment 25 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2010-03
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
25 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-01
Primary completion
2010-03
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Massachusetts General HospitalLead Sponsor
TakedaCollaborator
Investigators
1
David J. Miklowitz, Ph.D.Principal Investigator
Sites
1 total
Boston, United States
Facts & assertions
4 sourced
Enrollment
25
Phase
PHASE4
Primary Completion Date
2010-03
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
company
indication
investigator